Journal article

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (HSN1) vaccine in infants and children

Terry Nolan, Peter C Richmond, Neil T Formica, Katja Hoeschler, Maryanne V Skeljo, Tanya Stoney, Jodie McVernon, Gunter Hartel, Daphne C Sawlwin, Jillian Bennet, David Ryan, Russell L Basser, Maria C Zambon

VACCINE | ELSEVIER SCI LTD | Published : 2008


OBJECTIVE: Highly pathogenic avian influenza A virus (H5N1) is a leading candidate for the next influenza pandemic, and infants and children may play an important role in transmission in a pandemic. Our objective was to evaluate the safety and immunogenicity of a prototype inactivated, aluminium adjuvanted, split-virus, clade 1 H5N1 vaccine (A/Vietnam/1194/2004/NIBRG-14) in infants and children aged > or =6 months to or =1:20) and HI assays (95-100% > or =1:32), with 80-87% of children having MN antibody persistence (> or =1:20) up to 6 months post-vaccination. Additionally, robust cross-clade HI antibody responses were elicited following two doses. INTERPRETATION: Two doses of prototype 30..

View full abstract


Funding Acknowledgements

G. Hartel, N.T. Formica, D.C. Sawlwin, J. Bennet, D. Ryan and R.L. Basset are employees of CSL Limited; Parkville, VIC, Australia. M.V. Skeljo is a former employee of CSL Limited. T.M. Nolan and P.C. Richmond have received honorarium payments and travel support from CSL Limited for scientific advisory meetings on unrelated vaccine research. K. Hoschler and M.C. Zambon are employees of the Health Protection Agency, Colindale, UK, which received funding from CSL Limited to conduct the laboratory assays. All other authors have no conflict of interest.